Johnson & Johnson coronavirus vaccine wins FDA authorisation

The big pharmaceutical company's jab has some important advantages.

| More on:
coronavirus vaccine represented by gloved hand drawing down from syringe

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The United States now has a third coronavirus vaccine authorised for use. Johnson & Johnson (NYSE: JNJ)'s vaccine, developed by its subsidiary Janssen, received Emergency Use Authorisation (EUA) from the FDA on Saturday. This followed a unanimous vote by the regulator's vaccines and related biological products advisory committee that it do so.

In contrast to the two shots required for both of the other FDA-authorised coronavirus vaccines -- Moderna Inc (NASDAQ: MRNA)'s mRNA-1273 and Pfizer Inc (NYSE: PFE) and BioNTech (NASDAQ: BNTX)'s BNT162b2 -- Johnson & Johnson's is a one-shot inoculation. 

It also has relatively less burdensome storage requirements, as it can be kept for as long as three months in standard refrigeration temperatures of 36 to 46 degrees Fahrenheit.

The Johnson & Johnson vaccine demonstrated notably lower efficacy (72%) in late-stage testing compared the 95% or so of its two peers. However, 72% is still considered unusually high by vaccine development standards, plus Johnson & Johnson's was shown to be 100% efficacious in preventing hospitalisation and death. 

The Moderna and Pfizer/BioNTech shots were authorised in December and so far have been administered to nearly 15% of the US population. So it's likely that Johnson & Johnson's jab won't lap past them, no matter its advantages. It will, however, help push the inoculation rate up quickly.

Investors should be aware that Johnson & Johnson won't be making money from the vaccine during the pandemic. As it reiterated in the press release trumpeting the EUA, it will provide the jab "on a not-for-profit basis for emergency pandemic use."

The company added that it has already started to ship the vaccine, with the goal of delivering enough to inoculate over 20 million people in the US by the end of March. 100 million doses should be shipped by the end of June.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson and Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Alphabet's AI push is accelerating — Is the stock a buy now?

Alphabet is looking to be a big winner in artificial intelligence, defying skeptics.

Read more »

A man has computer-generated images rushing through his head indicating an AI (Artificial Intelligence) concept of a communication network.
International Stock News

Where Will Nvidia Be in 5 Years?

The AI infrastructure leader has had a phenomenal run in recent years.

Read more »

A woman smiles as she powers up her electric car using a fast charger.
International Stock News

Better EV Stock: Alphabet vs. Tesla (Hint: Robotaxis Are the Key)

Which company is better placed, and which is the better stock?

Read more »

woman watching Netflix and flicking the channel
International Stock News

1 Remarkable Stat That Highlights Just How Amazing Netflix Stock Has Been in Recent Years

Netflix has routinely been a market-beating stock, soaring around 150% in the past five years.

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
International Stock News

1 super artificial intelligence (AI) stock billionaire Bill Gates has 25% of his foundation's portfolio invested in

It's a company that Gates knows quite well.

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
International Stock News

5 reasons to buy Nvidia stock like there's no tomorrow

Nvidia's future should be even more exciting than its present.

Read more »

Hand with AI in capital letters and AI-related digital icons.
International Stock News

Prediction: This unstoppable artificial intelligence (AI) stock will join Nvidia, Microsoft, Apple, Amazon, and Alphabet in the $2 trillion club by year's end

The parent of Facebook, Instagram, and more could benefit more than anyone else from advancements in generative AI.

Read more »

Amazon boxes stacked up on a doorstep.
International Stock News

Should you buy Amazon stock before July 31?

Amazon is trailing the market this year.

Read more »